J. Kirchheiner

发表

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

J Licinio, J Kirchheiner, M. Wong, 2004, Molecular Psychiatry.

CYP2D6 in the brain: genotype effects on resting brain perfusion

J Kirchheiner, C. Maier, R. Viviani, 2011, Molecular Psychiatry.

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

Hans Lehrach, Markus Otto, Philippe Amouyel, 2011, Archives of general psychiatry.

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

C. Meisel, J. Brockmöller, I. Roots, 2003, British journal of clinical pharmacology.

Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?

Jürgen Brockmöller, Uwe Fuhr, U. Fuhr, 2005, Nature Reviews Drug Discovery.

Translating Pharmacogenomics: Challenges on the Road to the Clinic

Henk-Jan Guchelaar, Jesse J Swen, W. Assendelft, 2007, PLoS medicine.

Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol

J. Brockmöller, I. Roots, J. Kirchheiner, 2008, Journal of clinical psychopharmacology.

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

J Kirchheiner, J Lötsch, J. Lötsch, 2007, The Pharmacogenomics Journal.

AmpliChip CYP450 GeneChip®: A New Gene Chip That Allows Rapid and Accurate CYP2D6 Genotyping

Hilmar Luthe, Michael Oellerich, Jürgen Brockmöller, 2006, Therapeutic drug monitoring.

Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future?

R. Viviani, A. Seeringer, J. Kirchheiner, 2010, Current pharmaceutical design.

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

J. Brockmöller, A. Holstein, A. Plaschke, 2005, British journal of clinical pharmacology.

Genetic variants of the insulin receptor substrate‐1 are influencing the therapeutic efficacy of oral antidiabetics

I. Roots, A. Seeringer, J. Kirchheiner, 2010, Diabetes, obesity & metabolism.

Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways.

D. Gurwitz, M. Rehavi, J. Kirchheiner, 2010, Pharmacogenomics (London).

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P‐glycoprotein in HIV‐infected Patients

U. Fuhr, A. Jetter, C. Lehmann, 2008, Clinical pharmacology and therapeutics.

Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort.

W. März, B. Boehm, W. Renner, 2010, Pharmacogenomics.

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

A. Gaedigk, J. Kirchheiner, A. Kashuba, 2006, European Journal of Clinical Pharmacology.

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

C. Meisel, J. Brockmöller, I. Roots, 2004, Pharmacogenetics.

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide

J. Brockmöller, S. Vormfelde, I. Meineke, 2004, Clinical pharmacology and therapeutics.

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

K. Wernecke, J. Brockmöller, I. Roots, 2003, Journal of clinical psychopharmacology.

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

J. Brockmöller, I. Roots, I. Meineke, 2002, Pharmacogenetics.

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.

C. Meisel, J. Brockmöller, I. Roots, 2000, Pharmacogenomics.

Year : 2009 In vivo role of cytochrome P 450 2 E 1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans

U. Fuhr, M. Kinzig, F. Sörgel, 2009 .

Genotype and phenotype relationship in drug metabolism.

J. Brockmöller, I. Roots, I. Cascorbi, 2007, Ernst Schering Research Foundation workshop.

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

U. Fuhr, A. Jetter, G. Fätkenheuer, 2008, European Journal of Clinical Pharmacology.

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide

U. Fuhr, J. Brockmöller, F. Sörgel, 2004, European Journal of Clinical Pharmacology.

Hepatic Nuclear Factor 1α Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin

Wei Zhang, J. Kirchheiner, Honghao Zhou, 2008, Drug Metabolism and Disposition.

Sex-specific differences in side effects of psychotropic drugs: genes or gender?

A. Seeringer, T. Becker, J. Kirchheiner, 2009, Pharmacogenomics.

A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer’s disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF

F. Mottaghy, A. Ludolph, C. V. von Arnim, 2010, European journal of neurology.

Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction.

J. Svensson, A. Rane, B. Kammerer, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

U. Fuhr, A. Jetter, E. Schömig, 2010, Antiviral therapy.

CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best?

J. Kirchheiner, 2008, Clinical pharmacology and therapeutics.

University of Birmingham Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency

U. Fuhr, W. Arlt, D. Maiter, 2010 .

Clinical Consequences of Cytochrome P450 2C9 Polymorphisms

Jürgen Brockmöller, J. Brockmöller, J. Kirchheiner, 2005, Clinical pharmacology and therapeutics.

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

J. Brockmöller, P. Nürnberg, M. Toliat, 2007, The Pharmacogenomics Journal.

Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progress.

K. Aitchison, A. H. Maitland‐van der Zee, J. Kirchheiner, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

EFFECT OF PROPIVERINE ON CYTOCHROME P450 ENZYMES: A COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS

U. Fuhr, F. Sörgel, A. Jetter, 2005, Drug Metabolism and Disposition.

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity

U. Fuhr, U. Jaehde, A. Jetter, 2008, European Journal of Clinical Pharmacology.

Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate

J. Brockmöller, A. Seeringer, J. Kirchheiner, 2008, European Journal of Clinical Pharmacology.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

U. Fuhr, A. Lazar, J. Kirchheiner, 2008, Clinical pharmacokinetics.

Reproductive toxicology. Salicylazosulfapyridine.

H. Gelderblom, J. Swen, J. Kirchheiner, 1997, Environmental health perspectives.

Implications of pharmacogenetics for individualizing drug treatment and for study design

C. Meisel, J. Brockmöller, I. Roots, 2003, Journal of Molecular Medicine.

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

J. Sasse, J. Brockmöller, I. Roots, 2008, Pharmacogenomics.

Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging.

M. Bauer, N. Rasgon, P. Whybrow, 2003, Pharmacopsychiatry.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, C. Rodríguez-Antona, 2008, Pharmacogenomics.

Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

M. Haberl, J. Brockmöller, L. Wojnowski, 2002, Journal of the National Cancer Institute.

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

J. Brockmöller, M. Tzvetkov, I. Roots, 2005, Pharmacogenetics and genomics.

Therapeutic Drug Monitoring of Mirtazapine, Desmethylmirtazapine, 8-Hydroxymirtazapine, and Mirtazapine-N-oxide by Enantioselective HPLC With Fluorescence Detection

J. Brockmöller, I. Meineke, J. Kirchheiner, 2006, Therapeutic drug monitoring.

Serotonin syndrome with tramadol and citalopram.

J. Sasse, D. Kunz, R. Mahlberg, 2004, The American journal of psychiatry.

The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.

U. Fuhr, A. Jetter, U. Zanger, 2009, Basic & clinical pharmacology & toxicology.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

U. Fuhr, U. Klotz, J. Brockmöller, 2008, European Journal of Clinical Pharmacology.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Impact of the CYP2D6 Ultrarapid Metabolizer Genotype on Mirtazapine Pharmacokinetics and Adverse Events in Healthy Volunteers

J. Brockmöller, I. Roots, I. Meineke, 2004, Journal of clinical psychopharmacology.

Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects

J. Brockmöller, I. Meineke, J. Kirchheiner, 2007, Clinical pharmacology and therapeutics.

CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?

J. Brockmöller, I. Roots, J. Kirchheiner, 2008, Journal of analytical toxicology.

Pharmacogenetics of Oral Anticoagulants

U. Fuhr, A. Lazar, J. Kirchheiner, 2008, Clinical pharmacokinetics.

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.

M. Pirmohamed, F. Rosendaal, F. Kamali, 2009, Pharmacogenomics.

Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection.

J. Brockmöller, I. Roots, J. Kirchheiner, 2003, Journal of pharmaceutical and biomedical analysis.

Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach

U. Fuhr, A. Jetter, J. Kirchheiner, 2007, Clinical pharmacology and therapeutics.

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

J. Brockmöller, I. Roots, J. Kirchheiner, 2005, Clinical pharmacokinetics.

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

C. Meisel, J. Brockmöller, W. Rohde, 2002, Pharmacogenetics.

Healthy outcome under olanzapine treatment in a pregnant woman.

A. Berghöfer, J. Kirchheiner, D. Bolk-Weischedel, 2000, Pharmacopsychiatry.

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2

C. Meisel, J. Brockmöller, I. Roots, 2002, Clinical pharmacology and therapeutics.

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

J. Brockmöller, I. Roots, J. Kirchheiner, 2002, Clinical pharmacology and therapeutics.

Child and Adolescent Psychiatry and Mental Health Drug Monitoring in Child and Adolescent Psychiatry for Improved Efficacy and Safety of Psychopharmacotherapy

M. Gerlach, M. Kölch, J. Fegert, 2022 .

HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY

M. Schwab, J. Kirchheiner, 2009 .

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

J Kirchheiner, U. Fuhr, A. Lazar, 2008, The Pharmacogenomics Journal.

Clinical Pharmacology and Anticancer Drugs

C. Rodríguez-Antona, J. Kirchheiner, C. Rodríguez‐Antona, 2010 .

Response to Lithium Augmentation in Depression is Associated with the Glycogen Synthase Kinase 3-Beta −50T/C Single Nucleotide Polymorphism

M. Bauer, A. Heinz, T. Stamm, 2007, Biological Psychiatry.

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.

A. Seeringer, J. Kirchheiner, Angela Seeringer, 2007, Biochimica et biophysica acta.

Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports.

M. Romanos, U. Schulze, J. Kirchheiner, 2008, European eating disorders review : the journal of the Eating Disorders Association.

CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages

S. Kasper, J. Brockmöller, I. Roots, 2001, Acta psychiatrica Scandinavica.

Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan

U. Fuhr, U. Jaehde, A. Jetter, 2010, Clinical pharmacology and therapeutics.

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.

D. Gurwitz, A. Llerena, C. Rodríguez-Antona, 2009, Pharmacogenomics.

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.

J. Brockmöller, I. Roots, J. Kirchheiner, 2004, Personalized medicine.

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

D. Rujescu, H. Hakonarson, U. Lindenberger, 2015, Alzheimer's & Dementia.

Pharmacogenetics-guided dose modifications of antidepressants.

A. Seeringer, J. Kirchheiner, 2008, Clinics in laboratory medicine.

Contribution of allelic variations in transporters to the phenotype of drug response

D. Gründemann, E. Schömig, J. Kirchheiner, 2006, Journal of psychopharmacology.

Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education

G. Siest, J. Licinio, D. Gurwitz, 2005, The Pharmacogenomics Journal.

Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers

C. Meisel, I. Roots, U. Malzahn, 2006, European Journal of Clinical Pharmacology.

Assessment of urinary mephenytoin metrics to phenotype for CYP 2 C 19 and CYP 2 B 6 activity

U. Fuhr, U. Jaehde, A. Jetter, 2008 .

Cytochrome P 450 2 D 6 Genotyping Potential Role in Improving Treatment Outcomes in Psychiatric Disorders

C. Rodríguez-Antona, J. Kirchheiner, C. Rodríguez‐Antona, 2012 .

Cytochrome P450 2D6 Genotyping

C. Rodríguez-Antona, J. Kirchheiner, C. Rodríguez‐Antona, 2009, CNS drugs.

Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis.

R. Letón, C. Rodríguez-Antona, M. Robledo, 2009, Analytical biochemistry.

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics

C. Meisel, J. Brockmöller, M. Tzvetkov, 2004, Clinical pharmacology and therapeutics.

Pharmacogenetics‐Based New Therapeutic Concepts

Rolf Kaiser, Christian Meisel, Jürgen Brockmöller, 2004, Drug metabolism reviews.

Baseline Brain Perfusion and the Serotonin Transporter Promoter Polymorphism

David Comas, Roberto Viviani, Petra Beschoner, 2010, Biological Psychiatry.

In vivo Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans

U. Fuhr, M. Kinzig, F. Sörgel, 2009, Cancer Epidemiology Biomarkers & Prevention.

Effect of fluvastatin on CYP2C9 activity using warfarin as a probe

A. Gaedigk, J. Kirchheiner, S. Bauer, 2004 .

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers

Christian Meisel, Steffen Bauer, Jürgen Brockmöller, 2003, Clinical pharmacology and therapeutics.

Impact of the CYP2D6 ultra‐rapid metabolizer genotype on CIS‐ and trans‐doxepin pharmacokinetics and serotonin concentration in platelets

J. Brockmöller, I. Roots, I. Meineke, 2005 .

Population variability of CYP2C9 activity in caucasians: Effects of genotype versus enzyme induction

J. Kirchheiner, S. Bauer, J. Brockmöller, 2005 .

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.

Hong-Hao Zhou, Dong Guo, Bi-Lian Chen, 2009, Clinica chimica acta; international journal of clinical chemistry.

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

J. Sasse, J. Brockmöller, I. Roots, 2007, The Pharmacogenomics Journal.

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

C. Meisel, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers

J. Brockmöller, I. Roots, S. Vormfelde, 2009, Clinical pharmacology and therapeutics.

Characterization of a Functional Promoter Polymorphism of the Human Tryptophan Hydroxylase 2 Gene in Serotonergic Raphe Neurons

M. Lautenschlager, P. Zill, J. Priller, 2007, Biological Psychiatry.

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment

J. Brockmöller, M. Tzvetkov, I. Roots, 2008, Pharmacogenetics and genomics.

One Tablet or Two? Towards the Development of Pharmacogenomically Informed Drug Dose Individualization

R. Viviani, A. Seeringer, J. Kirchheiner, 2010 .

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

Wolfgang Rohde, Christian Meisel, Steffen Bauer, 2002, Clinical pharmacology and therapeutics.

Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics

J. Brockmöller, I. Roots, I. Gashaw, 2003, Clinical pharmacology and therapeutics.

Association of CYP2D6 genotypes and personality traits in healthy individuals.

J. Gallinat, U. Lang, T. Sander, 2006, Journal of clinical psychopharmacology.

Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection.

J. Brockmöller, I. Roots, J. Kirchheiner, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The role of human CYP 2 C 8 and CYP 2 C 9 variants in pioglitazone metabolism in vitro

U. Fuhr, A. Jetter, U. Zanger, 2009 .

Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents.

U. Fuhr, J. Kirchheiner, 2005, International journal of clinical pharmacology and therapeutics.

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

J. Brockmöller, A. Rane, B. Kammerer, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

U. Fuhr, J. Brockmöller, A. Jetter, 2006, Clinical pharmacology and therapeutics.

Evaluating algorithm-guided treatment for depression: The German Algorithm Project (GAP)

H. Möller, M. Bauer, M. Smolka, 2005 .

Running title : Effect of propiverine on cytochrome P 450 enzymes : a cocktail interaction study in healthy volunteers

U. Fuhr, F. Sörgel, A. Jetter, 2005 .

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].

A. Seeringer, J. Kirchheiner, 2008, Der Internist.

Brain Perfusion and the Serotonin ransporter Promoter Polymorphism oberto

Viviani, D. Comas, A. Rosa, 2022 .

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

J. Darbà, M. Pirmohamed, U. Siebert, 2010, Pharmacogenomics.

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

C. Meisel, J. Brockmöller, W. Rohde, 2004, Clinical pharmacokinetics.

Assessment of Alzheimer's disease risk genes with CSF-biomarker levels

Stefan Teipel, Harald Hampel, Goran Simic, 2013, Alzheimer's & Dementia.

GENES BY POPULATION PHARMACOKINETICS OF DEXTROMETHORPHAN

U. Fuhr, U. Jaehde, A. Jetter, 2017 .

Assessment of activity levels for CYP 2 D 6 * 1 , CYP 2 D 6 * 2 , and CYP 2 D 6 * 41 genes by population pharmacokinetics of dextromethorphan

U. Fuhr, U. Jaehde, A. Jetter, 2016 .

Serotonin transporter gene and response to lithium augmentation in depression

R. Kaiser, M. Bauer, M. Smolka, 2008, Psychiatric genetics.

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy

M. Gerlach, M. Kölch, J. Fegert, 2009 .

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

H. Lehrach, R. Tanzi, J. Lambert, 2011, Archives of general psychiatry.

Concise guide to the cytochrome P450 system: drug interaction principles for medical practice.

J. Kirchheiner, 2003 .

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.

M. Pirmohamed, F. Rosendaal, F. Kamali, 2009, Pharmacogenomics.

Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

J Kirchheiner, L. Bertilsson, H. Bruus, 2003, Pharmacopsychiatry.

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

U. Fuhr, J. Brockmöller, I. Meineke, 2008, Pharmacogenomics.

Translating Pharmacogenomics: Challenges on the Road to the Clinic

W. Assendelft, E. D. de Vries, H. Guchelaar, 2007, PLoS medicine.